ANA Investigates Biomarkers for Alzheimer's Disease

Mar 22, 2022

On today’s show, we’ll focus on the future of biomarkers in Alzheimer’s disease. We know that amyloid beta and tau protein deposit long before patients with Alzheimer’s develop symptoms. If we could use biomarkers to detect this pathology early, and treat patients early, could we prevent the progression to dementia? Our guests today are leaders in the development of biomarkers for Alzheimer’s disease - Dr. Suzanne Schindler, Associate Professor of Neurology at Washington University in St. Louis and Dr. Gil Rabinovici, Professor of Neurology and Radiology at the University of California San Francisco. They’ll talk with Dr. Doug Ney of UC Denver about the expanding role of biomarkers in Alzheimer’s prevention and treatment. Series 3, Episode 5

Featuring:

• Guests: Dr. Suzanne Schindler, Washington University at St. Louis & Dr. Gil Rabinovici, University of California at San Francisco
• Interviewer/Producer: Dr. Douglas Ney, University of Colorado
• Disclosures: Dr. Schindler disclosed that C2N Diagnostics provided data free of cost for her team to analyze. Dr. Rabinovici disclosed that he leads the New IDEAS study and has received research funding from Avid Radiopharmaceuticals, GE Healthcare, Life Molecular Imaging, Genentech; and is on scientific advisory boards for Eisai, J&J, Genentech, Eli Lilly, and Roche.